These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 10582896)

  • 1. Activity of gemifloxacin against penicillin- and ciprofloxacin-resistant Streptococcus pneumoniae displaying topoisomerase- and efflux-mediated resistance mechanisms.
    Heaton VJ; Goldsmith CE; Ambler JE; Fisher LM
    Antimicrob Agents Chemother; 1999 Dec; 43(12):2998-3000. PubMed ID: 10582896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antipneumococcal activities of gemifloxacin compared to those of nine other agents.
    Davies TA; Kelly LM; Pankuch GA; Credito KL; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 2000 Feb; 44(2):304-10. PubMed ID: 10639354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single- and multi-step resistance selection study of gemifloxacin compared with trovafloxacin, ciprofloxacin, gatifloxacin and moxifloxacin in Streptococcus pneumoniae.
    Nagai K; Davies TA; Dewasse BE; Jacobs MR; Appelbaum PC
    J Antimicrob Chemother; 2001 Sep; 48(3):365-74. PubMed ID: 11533001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cleavable-complex formation by wild-type and quinolone-resistant Streptococcus pneumoniae type II topoisomerases mediated by gemifloxacin and other fluoroquinolones.
    Yague G; Morris JE; Pan XS; Gould KA; Fisher LM
    Antimicrob Agents Chemother; 2002 Feb; 46(2):413-9. PubMed ID: 11796351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro selection of resistance to clinafloxacin, ciprofloxacin, and trovafloxacin in Streptococcus pneumoniae.
    Nagai K; Davies TA; Pankuch GA; Dewasse BE; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 2000 Oct; 44(10):2740-6. PubMed ID: 10991854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potent antipneumococcal activity of gemifloxacin is associated with dual targeting of gyrase and topoisomerase IV, an in vivo target preference for gyrase, and enhanced stabilization of cleavable complexes in vitro.
    Heaton VJ; Ambler JE; Fisher LM
    Antimicrob Agents Chemother; 2000 Nov; 44(11):3112-7. PubMed ID: 11036032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro susceptibility to gemifloxacin and trovafloxacin of Streptococcus pneumoniae strains exhibiting decreased susceptibility to ciprofloxacin.
    Fuentes F; Giménez MJ; Marco F; Alou L; Aguilar L; Prieto J
    Eur J Clin Microbiol Infect Dis; 2000 Feb; 19(2):137-9. PubMed ID: 10746503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamic activity of fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae.
    Zhanel GG; Roberts D; Waltky A; Laing N; Nichol K; Smith H; Noreddin A; Bellyou T; Hoban DJ
    J Antimicrob Chemother; 2002 May; 49(5):807-12. PubMed ID: 12003975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efflux and target mutations as quinolone resistance mechanisms in clinical isolates of Streptococcus pneumoniae.
    Broskey J; Coleman K; Gwynn MN; McCloskey L; Traini C; Voelker L; Warren R
    J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():95-9. PubMed ID: 10824039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates.
    Smith HJ; Walters M; Hisanaga T; Zhanel GG; Hoban DJ
    Antimicrob Agents Chemother; 2004 Oct; 48(10):3954-8. PubMed ID: 15388458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bactericidal activity of gemifloxacin and other quinolones against Streptococcus pneumoniae.
    Morrissey I; George JT
    J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():107-10. PubMed ID: 10824041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Purification of pneumococcal type II topoisomerases and inhibition by gemifloxacin and other quinolones.
    Morrissey I; George JT
    J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():101-6. PubMed ID: 10824040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antipneumococcal activity of DW-224a, a new quinolone, compared to those of eight other agents.
    Kosowska-Shick K; Credito K; Pankuch GA; Lin G; Bozdogan B; McGhee P; Dewasse B; Choi DR; Ryu JM; Appelbaum PC
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2064-71. PubMed ID: 16723567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of efflux pump gene pmrA in fluoroquinolone-resistant and -susceptible clinical isolates of Streptococcus pneumoniae.
    Piddock LJ; Johnson MM; Simjee S; Pumbwe L
    Antimicrob Agents Chemother; 2002 Mar; 46(3):808-12. PubMed ID: 11850265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determining the frequency of resistance of Streptococcus pneumoniae to ciprofloxacin, levofloxacin, trovafloxacin, grepafloxacin, and gemifloxacin.
    Evans ME
    Eur J Clin Microbiol Infect Dis; 2001 Dec; 20(12):883-5. PubMed ID: 11837640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro.
    Gootz TD; Zaniewski R; Haskell S; Schmieder B; Tankovic J; Girard D; Courvalin P; Polzer RJ
    Antimicrob Agents Chemother; 1996 Dec; 40(12):2691-7. PubMed ID: 9124824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluoroquinolone resistance in Streptococcus pneumoniae: evidence that gyrA mutations arise at a lower rate and that mutation in gyrA or parC predisposes to further mutation.
    Gillespie SH; Voelker LL; Ambler JE; Traini C; Dickens A
    Microb Drug Resist; 2003; 9(1):17-24. PubMed ID: 12705679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of gemifloxacin against Streptococcus pneumoniae isolates in Germany.
    Lemmen S; Al-Lahham A; Lütticken R; Reinert RR
    Chemotherapy; 2001; 47(2):104-9. PubMed ID: 11173811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo activity of gemifloxacin, moxifloxacin and levofloxacin against pneumococci with gyrA and parC point mutations in a sepsis mouse model measured with the all or nothing mortality end-point.
    Alkorta M; Giménez MJ; Vicente D; Aguilar L; Pérez-Trallero E
    Int J Antimicrob Agents; 2005 Feb; 25(2):163-7. PubMed ID: 15664487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamics to combat resistance.
    Woodnutt G
    J Antimicrob Chemother; 2000 Jul; 46 Suppl T1():25-31. PubMed ID: 10997596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.